Valneva Se (VALN) has released an update.
Valneva SE reports a successful financial year with total revenues of €153.7 million, a 12% increase in product sales over pre-pandemic levels, and significant advancements in their R&D pipeline including the launch of the first-ever chikungunya vaccine, IXCHIQ®. The company has improved its cash position to €126.1 million and provided an optimistic outlook for 2024, with expected total revenues between €170 million and €190 million, driven by the growth of its proprietary travel vaccines and new product launches. Valneva has strategically refocused on its core products and expects sustained profitability from 2025 onwards as it reduces third-party product sales and leverages its new manufacturing facilities.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
